Bleakley Financial Group’s Ionis Pharmaceuticals IONS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.17M Buy
14,793
+477
+3% +$35.9K 0.01% 607
2026
Q1
$1.07M Buy
14,316
+441
+3% +$34.8K 0.02% 513
2025
Q4
$1.1M Sell
13,875
-3
-0% -$226 0.02% 459
2025
Q3
$908K Sell
13,878
-4,251
-23% -$208K 0.02% 437
2025
Q2
$716K Sell
18,129
-4,155
-19% -$136K 0.02% 447
2025
Q1
$672K Buy
22,284
+5,342
+32% +$175K 0.02% 396
2024
Q4
$592K Buy
16,942
+264
+2% +$9.87K 0.02% 568
2024
Q3
$668K Buy
16,678
+338
+2% +$15.7K 0.02% 510
2024
Q2
$779K Buy
16,340
+111
+0.7% +$4.55K 0.02% 478
2024
Q1
$704K Buy
16,229
+3,990
+33% +$190K 0.02% 519
2023
Q4
$619K Buy
12,239
+41
+0.3% +$1.96K 0.02% 528
2023
Q3
$553K Sell
12,198
-340
-3% -$14K 0.02% 516
2023
Q2
$514K Buy
12,538
+291
+2% +$11.2K 0.02% 576
2023
Q1
$438K Sell
12,247
-937
-7% -$35.2K 0.01% 600
2022
Q4
$498K Buy
+13,184
New +$555K 0.02% 556

Other funds holding IONS

Bleakley Financial Group's IONS Position: Q2 2026 in Review

Bleakley Financial Group increased its Ionis Pharmaceuticals (IONS) stake by 3.3% in Q2 2026, buying an estimated $35.9K and bringing the position to 14,793 shares worth $1.17M. The position accounts for 0.01% of the portfolio, ranked #607.

Bleakley Financial Group first reported a position in IONS in Q4 2022 and has held it in 15 quarters since. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Bleakley Financial Group held 14,793 shares of Ionis Pharmaceuticals worth $1.17M as of Q2 2026.
  • Bleakley Financial Group bought 477 Ionis Pharmaceuticals shares in Q2 2026, an estimated $35.9K.
  • Ionis Pharmaceuticals made up 0.01% of Bleakley Financial Group's portfolio in Q2 2026, its #607 holding.
  • Bleakley Financial Group first reported a position in Ionis Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Bleakley Financial Group's 13F filing for Q2 2026, filed 5 Aug 2026.